Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at Chemotherapy Foundation Symposium XXII
12 November 2004 - 12:01AM
PR Newswire (US)
Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at
Chemotherapy Foundation Symposium XXII WESTMINSTER, Colo., Nov. 11
/PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH)
today announced that there will be a presentation on the Company's
lead clinical candidate, EFAPROXYN(TM) (efaproxiral) at the Twenty
Second Annual Chemotherapy Foundation Symposium taking place
November 10-13 at the Marriott Marquis Hotel in New York City. John
H. Suh, M.D., Director, Gamma Knife Center, Clinical Director,
Radiation Oncology, Brain Tumor Institute at the Cleveland Clinic
Foundation will give an oral presentation titled "Efaproxiral
(RSR13) as an Adjunct to Whole Brain Radiation Therapy for Patients
with Brain Metastases" on Friday, November 12, 2004, at 1:40 PM ET.
About EFAPROXYN EFAPROXYN is the first synthetic small molecule
designed to "sensitize" hypoxic (oxygen-deprived) areas of tumors
during radiation therapy by facilitating the release of oxygen from
hemoglobin, the oxygen-carrying protein contained within red blood
cells, and increasing the level of oxygen in tumors. The presence
of oxygen in tumors is an essential element for the effectiveness
of radiation therapy in the treatment of cancer. By increasing
tumor oxygenation at the time of treatment, EFAPROXYN has the
potential to enhance the efficacy of standard radiation therapy.
Unlike chemotherapeutics or other radiation sensitizers, EFAPROXYN
does not have to cross the blood brain barrier or enter the tumor
to be effective. About Allos Therapeutics, Inc. Allos Therapeutics,
Inc. is a biopharmaceutical company focused on developing and
commercializing innovative drugs for improving cancer treatments.
The company's lead clinical candidate, EFAPROXYN, is a synthetic
small molecule that has the potential to sensitize hypoxic (oxygen
deprived) tumor tissues and enhance the efficacy of standard
radiation therapy. In addition, Allos is developing PDX
(pralatrexate), a novel small molecule cytoxic injectable
antifolate (DHFR inhibitor) that is currently being investigated in
patients with non-small cell lung cancer and non-Hodgkin's
lymphoma. For more information, please visit the company's web site
at: http://www.allos.com/. Safe Harbor Statement This announcement
contains forward-looking statements that involve risks and
uncertainties. Future events may differ materially from those
discussed herein due to a number of factors, including, but not
limited to, risks and uncertainties detailed from time to time in
the Company's SEC filings, including its Annual Report on Form
10-K, as amended, for the year ended December 31, 2003. The
Company's product candidates are in various stages of development
and may never be fully developed in a manner suitable for
commercialization. If the company does not develop commercially
successful products, its ability to generate revenue will be
limited. If the Company is unable to raise additional capital when
required or on acceptable terms, it may have to significantly
delay, scale back or discontinue one or more of its drug
development programs. Delays in clinical trials, whether caused by
adverse events, patient enrollment rates, regulatory issues or
other factors, could adversely affect the Company's financial
position and prospects. Results from earlier clinical trials are
not necessarily predictive of future clinical results. If the
Company is unable to generate meaningful amounts of revenue or
cannot otherwise raise the necessary funds to support operations,
it may not be able to continue as a going concern. The Company
cautions investors not to place undue reliance on the forward
looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
assumes no responsibility to update such statements. DATASOURCE:
Allos Therapeutics, Inc. CONTACT: Jennifer Neiman, Manager,
Corporate Communications of Allos Therapeutics, Inc.,
+1-720-540-5227, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics (MM) News Articles